Benzinga | Nov 19, 2021 07:43AM EST

Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $185

Oppenheimer analyst Michael Wiederhorn maintains Teladoc Health (NYSE:TDOC) with a Outperform and lowers the price target from $200 to $185.